Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Nelarabine + Pegaspargase |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Nelarabine | Arranon | GW-506U78 | ||
| Pegaspargase | Oncaspar | PEG-asparaginase|PEG-ASP | Oncaspar (pegaspargase) is a pegylated version of L-asparaginase, which converts L-asparagine to ammonia and L-aspartic acid, reducing available asparagine resulting in decreased protein synthesis, inhibition of tumor cell proliferation, and increased apoptosis (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03808610 | Phase Ib/II | Cyclophosphamide + Dexamethasone + Venetoclax + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Rituximab + Venetoclax + Vincristine Sulfate Cytarabine + Methotrexate + Venetoclax Cytarabine + Methotrexate + Rituximab + Venetoclax Nelarabine + Pegaspargase Prednisone + Venetoclax + Vincristine Sulfate | Low-Intensity Chemotherapy and Venetoclax in Treating Patients with Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |